NCT04613596 2026-03-18
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Phase 2/3 Recruiting
Clinical Trials
4 trialsNCT06875310 2026-03-13
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
Phase 3 Recruiting
NCT05853575 2026-02-17
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
Phase 2 Recruiting
NCT06026410 2026-01-02
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting